| J9271 | Injection, pembrolizumab, 1 mg | 9,200 | $40 | $395.6K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 740 | $160 | $116.3K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 820 | $110 | $87.5K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 1,020 | $90 | $86.7K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 450 | $140 | $62.1K |
| J0897 | Injection, denosumab, 1 mg | 2,580 | $20 | $46.4K |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 6,320 | $10 | $37.9K |
| 99232 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making or… | 350 | $70 | $24.9K |
| 96367 | The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose… | 740 | $30 | $22.3K |
| 96365 | The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease. | 260 | $70 | $16.9K |